ADH

(redirected from Atypical Ductal Hyperplasia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms.

ADH:

see antidiuretic hormoneantidiuretic hormone
, polypeptide hormone secreted by the posterior pituitary gland. Its principal action is to regulate the amount of water excreted by the kidneys. Antidiuretic hormone (ADH), known also as vasopressin, causes the kidneys to resorb water directly from the
..... Click the link for more information. .

ADH

(biochemistry)

vasopressin

ADH

On drawings, abbr. for adhesive.

References in periodicals archive ?

The cases of atypical ductal hyperplasia associated with cancer reached a peak of 4.3 per 10,000 mammograms in 2003, but decreased to 3.3 in 2005.

Decrease in hormone therapy use may reduce breast cancer risk

In contrast, patients who were premenopausal when they had a breast biopsy showing atypical ductal hyperplasia had a 2.59-fold increased risk of subsequent breast cancer, whereas those who were postmenopausal at the time of their benign biopsy had a 4.04-fold increased breast cancer risk, Dr.

Atypical lobular hyperplasia has higher breast Ca risk than ductal

Estrogen receptor and cytokeratin 5 are reliable markers to separate usual ductal hyperplasia from atypical ductal hyperplasia and low-grade ductal carcinoma in situ.

Atypical Ductal Lesions of the Breast: Criteria, Significance, and Laboratory Updates

Atypical ductal hyperplasia at margin of breast biopsy--is re-excision indicated?

Breast Specimen Processing and Reporting With an Emphasis on Margin Evaluation: A College of American Pathologists Survey of 866 Laboratories

That worked out to an adjusted odds ratio for developing breast cancer of 2.76 for women with atypical ductal hyperplasia, 5.24 for those with atypical lobular hyperplasia, and 8.12 for women with both histologic abnormalities, she continued.

Breast cancer risk differs by subtype of atypical hyperplasia

(19) Specifically, 25 years after a diagnosis of atypical hyperplasia (atypical ductal hyperplasia and ALH) on biopsy, breast cancer (in situ or invasive) developed in 29% of women.

Isolated Atypical Lobular Hyperplasia Diagnosed on Breast Biopsy: Low Upgrade Rate on Subsequent Excision With Long-Term Follow-up

Can mammographic findings help discriminate between atypical ductal hyperplasia and ductal carcinoma in situ after needle core biopsy?

Breast biopsy: anesthesia, bleeding prevention, representative sampling, and rad/path concordance

Additional objectives included determining the incidence of significant pathologic findings (SPF), defined as occult carcinoma and atypical hyperplasia (including atypical ductal hyperplasia [ADH] and atypical lobular hyperplasia [ALH]), in RMP specimens.

Recommendations for Pathologic Evaluation of Reduction Mammoplasty Specimens: A Prospective Study With Systematic Tissue Sampling

Fibroadenoma is commonest seen in 27 cases (43.54%), benign breast disease in 15 cases (24.19%) and atypical ductal hyperplasia in 04 cases (6.45%), breast abscess in 04 cases (6.45%), galactocele in 04 cases (6.45%), mastitis in 03 cases(4.83%), fibrocystic disease in 02 cases(3.22%), intraductal papilloma in one case(1.61%), phylloides in one case (1.61%).

Spectrum of benign breast lesions: a cytologic study

Biopsies that showed atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, or flat epithelial atypia were grouped as atypical epithelial lesions.

Pathologic Findings of Breast Lesions Detected on Magnetic Resonance Imaging

(5,6) Common atypical pathologic findings in complex cystic breast masses include atypical ductal hyperplasia and atypical papilloma.

Cystic lesions of the breast: a study of fifty cases

Usual ductal hyperplasia (UDH) and atypical ductal hyperplasia (ADH)/low-grade ductal carcinoma in situ (LG-DCIS) are biologically distinct, intraductal, epithelial proliferations with different clinical implications.